U.S. Markets open in 4 hrs 53 mins
  • S&P Futures

    4,160.75
    +5.25 (+0.13%)
     
  • Dow Futures

    33,975.00
    +17.00 (+0.05%)
     
  • Nasdaq Futures

    13,932.75
    +35.50 (+0.26%)
     
  • Russell 2000 Futures

    2,230.30
    +1.00 (+0.04%)
     
  • Crude Oil

    64.12
    +0.74 (+1.17%)
     
  • Gold

    1,769.00
    -1.60 (-0.09%)
     
  • Silver

    25.95
    +0.11 (+0.44%)
     
  • EUR/USD

    1.2071
    +0.0031 (+0.2535%)
     
  • 10-Yr Bond

    1.6010
    0.0000 (0.00%)
     
  • Vix

    17.51
    +1.26 (+7.75%)
     
  • GBP/USD

    1.3994
    +0.0010 (+0.0714%)
     
  • USD/JPY

    108.4170
    +0.2670 (+0.2469%)
     
  • BTC-USD

    54,662.99
    -2,728.62 (-4.75%)
     
  • CMC Crypto 200

    1,232.82
    -66.14 (-5.09%)
     
  • FTSE 100

    6,970.09
    -29.99 (-0.43%)
     
  • Nikkei 225

    29,100.38
    -584.99 (-1.97%)
     

How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Every investor in CRISPR Therapeutics AG (NASDAQ:CRSP) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that have been privatized tend to have low insider ownership.

CRISPR Therapeutics is a pretty big company. It has a market capitalization of US$12b. Normally institutions would own a significant portion of a company this size. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about CRISPR Therapeutics.

View our latest analysis for CRISPR Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About CRISPR Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in CRISPR Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of CRISPR Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in CRISPR Therapeutics. The company's largest shareholder is ARK Investment Management LLC, with ownership of 11%. Capital Research and Management Company is the second largest shareholder owning 10% of common stock, and Nikko Asset Management Co., Ltd. holds about 5.2% of the company stock.

Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of CRISPR Therapeutics

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own some shares in CRISPR Therapeutics AG. Insiders own US$151m worth of shares (at current prices). Most would say this shows a good alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.

General Public Ownership

The general public holds a 22% stake in CRISPR Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Public Company Ownership

Public companies currently own 7.6% of CRISPR Therapeutics stock. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand CRISPR Therapeutics better, we need to consider many other factors. Be aware that CRISPR Therapeutics is showing 3 warning signs in our investment analysis , you should know about...

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.